Zai Lab Stock
Zai Lab Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- CEO
- Ying Du
- Employees
- 1,784
- Market cap
- $2.6 B
- IPO
- 20/09/2017
Zai Lab Limited is a healthcare biotechnology company headquartered in Shanghai, China. The company focuses on the discovery, development, and commercialization of innovative medical treatments, operating primarily in Mainland China and Hong Kong. Its therapeutic portfolio spans oncology, autoimmune conditions,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Zai Lab stock: price history
1D
-1.4%
1W
-7.2%
1M
-6.0%
6M
-4.1%
YTD
+31.5%
1Y
-19.6%
2Y
-11.4%
5Y
-77.3%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~56% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Zai Lab
Analyst assessment of Zai Lab
PRICE TARGET LOW
US$35.00
CONSENSUS
US$53.75
MEDIAN
US$52.50
PRICE TARGET HIGH
US$75.00
0
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 07/08/2026
Zai Lab stock metrics
P/E
-13.6
P/B
4.36
EV/EBITDA
-11.27
RETURN ON EQUITY
-8.4%
NET MARGIN
-47.8%
DEBT/EQUITY
0.42
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.4%
FLOAT SHARES
104,834,485
AVG. DAILY VOLUME (30D)
827,963
Insider transactions (SEC)
Chen Yajing
Chen Yajing
Chen Yajing
Chen Yajing
Chen Yajing
Institutional holders
Comparable stocks
Frequently asked questions about Zai Lab stock
What does Zai Lab do?
Zai Lab Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in China.
The CEO is Ying Du, the company employs around 1,784 people.
The IPO was on 20/09/2017; the stock trades on NASDAQ under the ticker ZLAB.
What do analysts say about Zai Lab stock?
11 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$53.75, ranging from US$35.00 to US$75.00, with a median of US$52.50.
This is an external assessment, not a statement by Market Jury.
When does Zai Lab report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 56% stronger than usual.
Does Zai Lab pay a dividend?
No, Zai Lab currently does not pay a dividend.
Which stocks are comparable to Zai Lab?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Zai Lab stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zai Lab against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.